Source:http://linkedlifedata.com/resource/pubmed/id/10578156
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
10
|
| pubmed:dateCreated |
2000-1-5
|
| pubmed:abstractText |
Adverse events were analyzed in 94 normal donors who underwent PBSC harvest with G-CSF. The median dose of G-CSF was 9.7 microg/kg/day (range, 2.0-16.7), and the duration of administration was 4-6 days. Frequent symptoms were bone pain (71%), general fatigue (33%), headache (28%), insomnia (14%), anorexia (11%), nausea and/or vomiting (11%). One donor (1%) developed grade 3 toxicity bone pain (WHO criteria). WBC counts and ANC increased during G-CSF administration. After leukapheresis, three donors (3%) developed grade 3 toxicity neutropenia. Platelet counts decreased after leukapheresis. Three donors (3%) developed grade 3 thrombocytopenia. The means of both ALP and LDH increased approximately 1.9-fold compared with pretreatment levels. In one pediatric donor (1%), ALP was elevated to the grade 3 toxicity level. From multivariate analysis, the incidence of bone pain increased when G-CSF was given at a dose of 8.8 microg/kg/day or more, headaches were frequent in donors younger than 35 years, and the incidence of nausea and/or vomiting was high in female donors. The peak levels of WBC counts and ANC and post-treatment level of LDH increased in correspondence with the escalation of G-CSF dose. All adverse events normalized on follow-up evaluation. In conclusion, although PBSC harvest for normal donors is acceptable, care must be taken for all donors in terms of their sex and age as well as the G-CSF dose. We recommend less than 8.8 microg/kg/day as the G-CSF dose for PBSC mobilization in normal donors.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0268-3369
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
24
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1065-71
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:10578156-Adolescent,
pubmed-meshheading:10578156-Adult,
pubmed-meshheading:10578156-Blood Component Removal,
pubmed-meshheading:10578156-Blood Donors,
pubmed-meshheading:10578156-Child,
pubmed-meshheading:10578156-Fatigue,
pubmed-meshheading:10578156-Female,
pubmed-meshheading:10578156-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:10578156-Headache,
pubmed-meshheading:10578156-Hematopoietic Stem Cell Mobilization,
pubmed-meshheading:10578156-Humans,
pubmed-meshheading:10578156-Leukocyte Count,
pubmed-meshheading:10578156-Male,
pubmed-meshheading:10578156-Middle Aged,
pubmed-meshheading:10578156-Multivariate Analysis,
pubmed-meshheading:10578156-Nausea,
pubmed-meshheading:10578156-Neutropenia,
pubmed-meshheading:10578156-Pain,
pubmed-meshheading:10578156-Platelet Count,
pubmed-meshheading:10578156-Sleep Initiation and Maintenance Disorders,
pubmed-meshheading:10578156-Vomiting
|
| pubmed:year |
1999
|
| pubmed:articleTitle |
Peripheral blood stem cell mobilization and apheresis: analysis of adverse events in 94 normal donors.
|
| pubmed:affiliation |
Division of Hematology, Department of Internal Medicine, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study
|